T News

MUTABILIS ANNOUNCES COLLABORATION WITH ROCHE TO DEVELOP A NEW CLASS OF ANTIBIOTICS TO TREAT INFECTIONS CAUSED BY WHO CRITICAL PRIORITY PATHOGENS

By: | Tags: | Comments: 0

Collaboration sets sight on a new age where novel classes of antibiotics and personalized health care options will be available

(PARIS, France, February 1st, 2022) – Mutabilis, a biotech based in Romainville, France, announced today that it has entered into a Research Collaboration and License Agreement with Roche on its 2G-Dabocins program.


You must be logged in to post a comment.